Significance of autologous interleukin-6 production in the HA22T/VGH cell model of hepatocellular carcinoma

Annals of the New York Academy of Sciences

Volumn 1089, Issue , 2006, Pages 268-275

  Labbozzetta, Manuela ^a   Notarbartolo, Monica ^a   Poma, Paola ^a   Giannitrapani, Lydia ^a   Cervello, Melchiorre ^b   Montalto, Giuseppe ^a   D'Alessandro, Natale ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

Author keywords

Autocrine cell growth stimulatory loop; Hepatocellular carcinoma; Interleukin 6; NF B

Indexed keywords

CURCUMIN; DEHYDROXYMETHYLEPOXYQUINOMICIN; GLYCOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; ANTIBODY; BENZAMIDE DERIVATIVE; CYCLOHEXANONE DERIVATIVE; GLYCOPROTEIN GP 130; IL6R PROTEIN, HUMAN; UNCLASSIFIED DRUG;

CANCER CELL CULTURE; CELL GROWTH; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIGAND BINDING; LIVER CELL CARCINOMA; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ARTICLE; BIOLOGICAL MODEL; BIOSYNTHESIS; CELL CULTURE; CELL MEMBRANE; CHEMISTRY; DRUG ANTAGONISM; GENETICS; LIVER TUMOR; METABOLISM;

ANTIBODIES; BENZAMIDES; CARCINOMA, HEPATOCELLULAR; CELL MEMBRANE; CURCUMIN; CYCLOHEXANONES; CYTOKINE RECEPTOR GP130; HUMANS; INTERLEUKIN-6; LIVER NEOPLASMS; MODELS, BIOLOGICAL; NF-KAPPA B; RECEPTORS, INTERLEUKIN-6; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 33847769603     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1386.014     Document Type: Conference Paper

References (23)

1. KAWANO, M., T. HIRANO, T. MATSUDA, et al. 1988. Autocrine generation and requirement of BSF/IL-6 for human multiple myelomas. Nature 332: 83-85.
2. MIKI, S., M. IWANO, Y. MIKI, et al. 1989. Interleukin-6 (IL-6) functions as an autocrine growth factor in renal cell carcinoma. FEBS Lett. 250: 607-610.
3. SIEGALL, C.B., G. SCHWAB, R.P. NORDAN, et al. 1990. Expression of the interleukin-6 receptor and interleukin-6 in prostate carcinoma cells. Cancer Res. 50: 7786-7788.
4. BORSELLINO, N., B. BONAVIDA, G. CILIBERTO, et al. 1999. Blocking signalling through the gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to VP-16 and CDDP-mediated cytotoxicity. Cancer 85: 134-144.
5. ONOZAKI, K., Y. AKIYAMA, A. OKANO, et al. 1989. Synergistic regulatory effect of interleukin 6 and interleukin 1 on the growth and differentiation of human and mouse myeloid leukemic cell lines. Cancer Res. 49: 3602-3607.
6. MAEKAWA, T., D. METCALF & D.P. GEARING. 1990. Enhanced suppression of human myeloid leukemic cell lines by combinations of IL-6, LIF, GM-CSF and G-CSF. Int. J. Cancer 45: 353-358.
7. CHEN, L., L.M. SHULMAN & M. REVEL. 1991. IL-6 receptors and sensitivity to growth inhibition by IL-6 in clones of human breast carcinoma cells. J. Biol. Regul. Homeost. Agents 5: 125-136.
8. TAKIZAWA, H., T. OHTOSHI, K. OHTA, et al. 1993. Growth inhibition of human lung cancer cell lines by interleukin 6 in vitro: a possible role in tumor growth via an autocrine mechanism. Cancer Res. 53: 4175-4181.
9. LU, C. & R.S. KERBEL. 1993. Interleukin 6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J. Cell. Biol. 120: 1281-1288.
10. FALKSON, G., J.M. MACINTYRE & C.G. MOERTEL. 1994. Primary liver cancer. Cancer 54: 977-980.
11. HUGGETT, A.C., C.P. FORD & S.S. THORGEIRSSON. 1989. Effects of interleukin 6 on the growth of normal and transformed rat liver cells in culture. Growth Factors 2: 83-89.
12. CRESSMANN, D.E., L.E. GREENBAUM, R.A. DEANGELIS, et al. 1996. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274: 1379-1383.
13. MAIONE, D., E. DI CARLO, W. LI, et al. 1998. Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J. 17: 5588-5597.
14. CERVELLO, M., M. NOTARBARTOLO, M. LANDINO, et al. 2001. Downregulation of wild-type beta-catenin expression by interleukin 6 in human hepatocarcinoma HepG2 cells: a possible role in the growth-regulatory effects of the cytokine? Eur. J. Cancer 37: 512-519.
15. KLAUSEN, P., L. PEDERSEN, J. JURLANDER & H. BAUMANN. 2000. Oncostatin M and interleukin 6 inhibit cell cycle progression by prevention of p27kip1 degradation in HepG2 cells. Oncogene 19: 3675-3683.
16. KIM, H. & H. BAUMANN. 1999. Dual signaling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells. Mol. Cell. Biol. 19: 5326-5338.
17. MORAN, D.M., N. MAYES, L.G. KONIARIS, et al. 2005. Interleukin-6 inhibits cell proliferation in a rat model of hepatocellular carcinoma. Liver Int. 25: 445-457.
18. GIANNITRAPANI, L., M. CERVELLO, M. SORESI, et al. 2002. Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma. Ann. N.Y. Acad. Sci. 963: 46-52.
19. KUMAGAI, N., K. TSUCHIMOTO, S. TSUNEMATSU, et al. 2002. Inhibition of growth of human hepatoma cells by dual-function antisense IL-6 oligonucleotides. Hepatol. Res. 22: 119-126.
20. POMA, P., M. NOTARBARTOLO, M. LABBOZZETTA, et al. 2006. Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production. Int. J. Oncol. 28: 923-930.
21. HIRANO, T., K. NAKAJIMA & M. HIBI. 1997. Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev. 8: 241-252.
22. JOHSTOCK, T., J. MULLBERG, S. OZBEK, et al. 2001. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur. J. Biochem. 268: 160-167.
23. ALBERTI, L., M.C. THOMACHOT, T. BACHELOT, et al. 2004. IL-6 as an intracrine growth factor for renal carcinoma cell lines. Int. J. Cancer 111: 653-661.